Impact of tumor number on the efficacy of lenvatinib in borderline resectable hepatocellular carcinoma
The presence of a single tumor may be a crucial factor in the use of Lenvatinib for borderline HCC.
Authors
- Shigeto Ochiai (ORCID: https://orcid.org/0000-0002-1445-4869)
- Katsuya Kitamura (ORCID: https://orcid.org/0000-0003-1556-7467)
- Takahiro Gunji (ORCID: https://orcid.org/0000-0002-4658-6882)
- Naokazu Chiba (ORCID: https://orcid.org/0000-0002-1846-5987)
- Shigeyuki Kawachi (ORCID: https://orcid.org/0000-0002-1623-4181)
- Toru Sano
- Masashi Nakagawa
- Junichi Taira
- Takumi Seichi
Institutions
- Tokyo Medical University Hachioji Medical Center (JP)
Publication Details
- Journal
- Langenbeck s Archives of Surgery
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1007/s00423-025-03867-6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00